Showing 8881-8890 of 23044 results for "".
Use of Wearable Fitness Technology Does Not Improve Weight Loss
https://reachmd.com/programs/the-jama-report/use-wearable-fitness-technology-does-not-improve-weight-loss/8359/A new JAMA study reports that using fitness wearables did not result in more weight loss among a group of obese and overweight young adults.Universal Implications of DES
https://reachmd.com/programs/clinicians-roundtable/universal-implications-of-des/686/In long term data presented from the RAVEL trial, the original trial reporting a remarkable decrease in the rate of restenosis with DES, the long-term incidence of death or heart attack was not significantly different between DES and bare metal stents.The Female Neurosurgeon's Perspective
https://reachmd.com/programs/clinicians-roundtable/the-female-neurosurgeons-perspective/1121/Dr. Katrina Firlik, author of "Another Day in the Frontal Lobe: a Brain Surgeon Exposes Life on the Inside" discusses being female in the male dominated specialty, neurosurgery.Sexual Problems of Long Term Cancer Survivors
https://reachmd.com/programs/clinicians-roundtable/sexual-problems-of-long-term-cancer-survivors/1467/Why do the sexual problems of long term cancer survivors deserve special attention? Dr. Shira Johnson discusses with Dr. Stacy Lindau the study she and her colleagues conducted which is published in the August 2007 issue of Gynecologic Oncology.Are You in a Groove or in a Rut?
https://reachmd.com/programs/clinicians-roundtable/are-you-in-a-groove-or-in-a-rut/1216/Join Dr. Linda Clever, founder of RENEW, a not-for-profit aimed at helping people maintain and regain enthusiasm help you identify and improve your own psyche in your medical practice.The Challenging Demands Faced by the Neurosurgeon
https://reachmd.com/programs/clinicians-roundtable/the-challenging-demands-faced-by-the-neurosurgeon/1120/Dr. Katrina Firlik, author of "Another Day in the Frontal Lobe: a Brain Surgeon Exposes Life on the Inside" discusses the practice of neurosurgery.ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
https://reachmd.com/programs/project-oncology/ctdna-immunotherapy-survival-mibc-imvigor011/36307/Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personRethinking PBC Care: Inside the RESPONSE Trial
https://reachmd.com/programs/gi-insights/primary-biliary-cholangitis-care-response-trial/49147/The phase 3 RESPONSE trial evaluated the efficacy and safety of seladelpar, a selective PPAR delta agonist, in patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodeoxycholic acid. Tune in to hear Dr. Gideon Hirschfield and Dr. Brian McDonough discuss the design andRethinking Hepatotoxicity Risk in Oral Psoriasis Therapies
https://reachmd.com/programs/Audioabstracts/hepatotoxicity-risk-oral-psoriasis-therapies/39677/Liver toxicity is a critical yet underrecognized concern associated with oral psoriasis therapies, with potential long-term consequences for patient safety and quality of care. Join Ryan Quigley as he explores findings from a recent review examining the hepatic safety of four key systemic treatmentsTiming Meningococcal Vaccines in gMG: Challenges and Considerations
https://reachmd.com/programs/neurofrontiers/timing-meningococcal-vaccines-in-gmg-challenges-and-considerations/32861/Evolving vaccination guidelines and varying clinical opinions have created uncertainty around the timing of meningococcal immunization in patients with generalized myasthenia gravis (gMG). Tune in to hear Dr. Michael Weiss, who spoke with ReachMD at the AANEM 2025 Annual Meeting, discuss how he bala